New NGS-Assay for HRD determination
Detection of mutations in 20 HRR genes and determination of the HRD status
The AmoyDx® HRD Complete Panel is an advanced development of the AmoyDx® HRD Focus Panel, which is already established in many laboratories for determining homologous recombination deficiency (HRD).
In both NGS assays, in addition to the BRCA1/2 mutational status, genomic instability is determined based on 24,000 SNPs, which are evenly distributed throughout the genome. The AmoyDx® HRD Complete Panel can be further used to detect SNVs, InDels and homozygous deletions in 20 genes involved in homologous recombination repair (HRR).
Please find a detailed description of the AmoyDx® HRD Complete Panel here.
This product is for research use only (RUO)
Further topics
Sarcoma Awareness Month
The new GATA antibody
A recently conducted study has shown that TRPS1 is expressed very highly in triple-negative breast cancer (TNBC). Expression was significantly higher than the GATA3 expression in metaplastic (85% vs. 21%) and non-metaplastic (86% vs. 51%) TNBC. Accordingly, TRPS1 has proven to be a highly specific and sensitive marker for all types of breast cancer, in particular TNBC. (Di Ai et al.; "TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Mod Pathol 34: 710-719, 2021)
